cancer is… and in the way that we
treat patients with cancer. This has
led to significant decreases in cancer
mortality rates on an annual basis.
The majority of cancer researchers
agree that these are exciting times
and that the pace of discovery and
application of new knowledge to
patient care is rapidly accelerating.”
–Jose Baselga, M.D., Ph.D., Physician-in-Chief, Memorial Sloan Kettering Cancer Center, New York, NY, President of the American Association for Cancer Research351
References
1. American Cancer Society. “The History of Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/002048-pdf.pdf 2. American Cancer Society. “Cancer Facts and Figures 2016.” http://www.cancer.org/acs/groups/content/@research/documents/
document/acspc-047079.pdf
3. American Cancer Society. “Cancer Facts and Figures 2016.” http://www.cancer.org/acs/groups/content/@research/documents/ document/acspc-047079.pdf
4. McGinley, L. “The list of cancers that can be treated by immunotherapy keeps growing.” The Washington Post. https://www. washingtonpost.com/news/to-your-health/wp/2016/04/19/breakthrough-cancer-therapy-shows-growing-promise/
5. American Cancer Society. “Cancer Facts & Figures 2015.” http://www.cancer.org/acs/groups/content/@editorial/documents/document/ acspc-044552.pdf
6. American Academy of Dermatology. “Skin Cancer.” https://www.aad.org/media-resources/stats-and-facts/conditions/skin-cancer 7. American Academy of Dermatology. “Skin Cancer.” https://www.aad.org/media-resources/stats-and-facts/conditions/skin-cancer 8. American Cancer Society. “What are the survival rates for melanoma skin cancer, by stage?” http://www.cancer.org/cancer/skincancer-
melanoma/detailedguide/melanoma-skin-cancer-survival-rates
9. Melanoma Research Foundation. “Metastatic Melanoma.” http://www.melanoma.org/understand-melanoma/what-is-melanoma/ metastatic-melanoma
10. Cancer Research Institute. “Cancer Immunotherapy: Melanoma.” http://www.cancerresearch.org/cancer-immunotherapy/impacting-all- cancers/melanoma
11. Melanoma Research Foundation. “What is Melanoma?” http://www.melanoma.org/understand-melanoma/what-is-melanoma
12. American Cancer Society. “What are the survival rates for melanoma skin cancer, by stage?” http://www.cancer.org/cancer/skincancer- melanoma/detailedguide/melanoma-skin-cancer-survival-rates
13. CancerProgress.Net. “Progress & Timeline: Melanoma.” http://cancerprogress.net/timeline/melanoma
14. Bhatia, S, Tykodi, SS, Thompson, JA. “Treatment of Metastatic Melanoma: An Overview.” Oncology. 2009. 23(6), 488-496. http:// www.ncbi.nlm.nih.gov/pmc/articles/PMC2737459/pdf/nihms129601.pdf
15. Korn, E, et al. “Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials.” Journal of Clinical Oncology. 2008. 26(4), 527-534.
16. American Cancer Society. “What’s new in research and treatment of melanoma skin cancer?” http://www.cancer.org/cancer/skincancer- melanoma/detailedguide/melanoma-skin-cancer-new-research
17. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
18. American Cancer Society. “Cancer Immunotherapy.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003013-pdf.pdf 19. Columbus, G. “American Society of Clinical Oncology Names Immunotherapy ‘Cancer Advance of the Year’.” Cure. February 5, 2016.
http://www.curetoday.com/articles/american-society-of-clinical-oncology-names-immunotherapy-cancer-advance-of-the-year 20. American Society of Clinical Oncology (ASCO). “Clinical Cancer Advances 2016.” http://www.cancerprogress.net/sites/cancerprogress.
net/files/asco-cca16-web-updated.pdf
21. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
22. U.S. Food and Drug Administration. “FDA approves new treatment for a type of late-stage skin cancer.” March 25, 2011. http://www. fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm1193237.htm
23. American Cancer Society. “Melanoma Skin Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf 24. American Cancer Society. “What’s new in research and treatment of melanoma skin cancer?” http://www.cancer.org/cancer/skincancer-
melanoma/detailedguide/melanoma-skin-cancer-new-research
25. Melanoma Research Foundation (MRF). “FDA Approval of New Melanoma Therapy Changes Landscape for Patients.” March 25, 2011. http://www.melanoma.org/about-us/news-press-room/press-releases/fda-approval-new-melanoma-therapy-changes-landscape-patients 26. American Cancer Society. “Cancer Immunotherapy.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003013-pdf.pdf 27. U.S. Food and Drug Administration. “FDA approves Yervoy to reduce the risk of melanoma returning after surgery.” October 28, 2015.
28. Pollack, A. “Drug Helps Defense System Fight Cancer.” The New York Times. June 1, 2012. http://www.nytimes.com/2012/06/02/ business/drug-helps-immune-system-fight-cancer.html?_r=0
29. Dolan, D, Gupta, S. “PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy.” Cancer Control. July 2014. https:// moffitt.org/media/1307/231.pdf
30. U.S. Food and Drug Administration. “FDA approves Keytruda for advanced melanoma.” September 4, 2014. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
31. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
32. U.S. Food and Drug Administration. “Pembrolizumab label updated with new clinical trial information.” Last updated December 21, 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm478493.htm
33. American Society of Clinical Oncology. “PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma: First Report of 36-month Overall Survival Data from Patients in Early-Stage Study.” May 18, 2016. https://www.asco.org/ about-asco/press-center/news-releases/pd-1-inhibitor-pembrolizumab-provides-long-term-survival#sthash.3KIldxX2.dpuf
34. U.S. Food and Drug Administration. “FDA approves Opdivo for advanced melanoma.” December 22, 2014. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm
35. American Association for Cancer Research. “Transforming Lives Through Research.” http://cancerprogressreport.org/2014/Pages/ transforming.aspx?Page=10
36. U.S. Food and Drug Administration. “Nivolumab in combination with ipilimumab.” Last updated October 1, 2015. http://www.fda.gov/ Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
37. Bristol-Myers Squibb. “Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1.” January 23, 2016. http://news.bms.com/press-release/bmy/bristol-myers- squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-receives-expanded
38. American Association for Cancer Research. “Transforming Lives Through Research.” http://cancerprogressreport.org/2014/Pages/ transforming.aspx?Page=10
39. American Society of Clinical Oncology. “PD-1 Inhibitor Pembrolizumab Provides Long-Term Survival Benefit for Patients With Advanced Melanoma: First Report of 36-month Overall Survival Data from Patients in Early-Stage Study.” May 18, 2016. https://www.asco.org/ about-asco/press-center/news-releases/pd-1-inhibitor-pembrolizumab-provides-long-term-survival#sthash.3KIldxX2.dpuf
40. CancerProgress.Net. “Progress & Timeline: Melanoma.” http://cancerprogress.net/timeline/melanoma
41. American Cancer Society. “What’s new in research and treatment of melanoma skin cancer?” http://www.cancer.org/cancer/skincancer- melanoma/detailedguide/melanoma-skin-cancer-new-research
42. American Cancer Society. “What’s new in research and treatment of melanoma skin cancer?” http://www.cancer.org/cancer/skincancer- melanoma/detailedguide/melanoma-skin-cancer-new-research
43. U.S. Food and Drug Administration. “FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer.” August 17, 2011. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm268241.htm
44. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
45. Flaherty KT, et al. “Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.” New England Journal of Medicine. 2012. (367):1694–703. http://www.nejm.org/doi/full/10.1056/NEJMoa1210093
46. U.S. Food and Drug Administration. “FDA approves Cotellic as part of combination treatment for advanced melanoma.” November 10, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm
47. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
48. U.S. Food and Drug Administration. “FDA approves first-of-its-kind product for the treatment of melanoma.” October 27, 2015. http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm
49. Skin Cancer Foundation. “Treatment of Metastatic Melanoma: A New World Opens.” http://www.skincancer.org/skin-cancer-information/ melanoma/melanoma-treatments/treatment-of-metastatic-melanoma
50. Adis R&D Insight Database. Accessed May 2016.
51. American Association for Cancer Research. “AACR Cancer Progress Report 2014: Transforming Lives Through Research.” http:// cancerprogressreport.org/2014/Documents/AACR_CPR_2014.pdf
52. Morrison, C. “‘Financial toxicity’ looms as cancer combinations proliferate.” Nature Biotechnology. August 7, 2015. http://www.nature. com/nbt/journal/v33/n8/full/nbt0815-783.html
53. Morrison, C. “‘Financial toxicity’ looms as cancer combinations proliferate.” Nature Biotechnology. August 7, 2015. http://www.nature. com/nbt/journal/v33/n8/full/nbt0815-783.html
54. American Cancer Society. “Cancer Facts and Figures 2016.” http://www.cancer.org/acs/groups/content/@research/documents/ document/acspc-047079.pdf
55. National Breast Cancer Foundation. “Breast Cancer Facts.” http://www.nationalbreastcancer.org/breast-cancer-facts
56. American Cancer Society. “Cancer Facts and Figures 2016.” http://www.cancer.org/acs/groups/content/@research/documents/ document/acspc-047079.pdf
57. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 58. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/
documents/document/acspc-046381.pdf
59. National Cancer Institute SEER Program. “SEER Stat Fact Sheets: Female Breast Cancer.” http://seer.cancer.gov/statfacts/html/breast. html
60. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-046381.pdf
61. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 62. American Cancer Society. “What are the risk factors for breast cancer?” http://www.cancer.org/cancer/breastcancer/detailedguide/
breast-cancer-risk-factors
63. National Cancer Institute. “BRCA1 and BRCA2: Cancer Risk and Genetic Testing.” http://www.cancer.gov/about-cancer/causes- prevention/genetics/brca-fact-sheet
64. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-046381.pdf
65. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-046381.pdf
66. Susan G. Komen Foundation. “Molecular Subtypes of Breast Cancer.” http://ww5.komen.org/BreastCancer/SubtypesofBreastCancer.html 67. National Cancer Institute. “Breast Cancer Treatment–Patient Version.” http://www.cancer.gov/types/breast/patient/breast-treatment-
pdq#section/_222
68. National Cancer Institute. “Breast Cancer Treatment–Patient Version.” http://www.cancer.gov/types/breast/patient/breast-treatment- pdq#section/_222
69. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 70. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 71. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 72. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/
documents/document/acspc-046381.pdf
73. The ASCO Post, “ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Nonmetastatic Hormone Receptor–Positive Breast Cancer.” http://www.ascopost.com/News/16262
74. U.S. Food and Drug Administration. “Paving the Way for Personalized Medicine - FDA’s Role in a New Era of Medical Product Development.” October 2013. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf 75. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf
76. National Cancer Institute. “Trastuzumab after Chemotherapy Is Effective in HER2-Positive Breast Cancer.” http://www.cancer.gov/types/ breast/research/trastuzumab-after-chemo
77. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-046381.pdf
78. U.S. Food and Drug Administration. “FDA Expands Use of Herceptin for Early Stage Breast Cancer After Primary Therapy.” November 16, 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108788.htm
79. American Cancer Society. “Targeted therapy for breast cancer.” http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer- treating-targeted-therapy
80. Susan G. Komen Foundation. “Neoadjuvant Therapies.” http://ww5.komen.org/BreastCancer/Neoadjuvant.html
81. U.S. Food and Drug Administration. “FDA Approves Tykerb for Advanced Breast Cancer Patients.” March 13, 2007. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2007/ucm108866.htm
82. U.S. Food and Drug Administration. “Paving the Way for Personalized Medicine - FDA’s Role in a New Era of Medical Product Development.” October 2013. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421.pdf 83. U.S. Food and Drug Administration. “FDA Approves Pertuzumab.” June 8, 2012. http://www.fda.gov/Drugs/InformationOnDrugs/
ApprovedDrugs/ucm307592.htm
84. National Cancer Institute. “FDA Approval for Pertuzumab.” September 30, 2013. http://www.cancer.gov/about-cancer/treatment/drugs/ fda-pertuzumab#Anchor-MetastatiHER2
85. Susan G. Komen Foundation. “Progress in Treating HER2/NEU-Positive Breast Cancers.” http://ww5.komen.org/KomenPerspectives/ Progress-in-treating-HER2/neu-positive-breast-cancers.html
86. T. Hallam. “Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter.” Scientific American. http://blogs. scientificamerican.com/guest-blog/antibody-drug-conjugates-and-cancer-treatment-making-smart-bombs-smarter/
87. U.S. Food and Drug Administration. “FDA approves new treatment for late-stage breast cancer.” February 22, 2013. http://www.fda. gov/newsevents/newsroom/pressannouncements/ucm340704.htm
88. U.S. Food and Drug Administration. “FDA approves Afinitor for advanced breast cancer.” July 20, 2012. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312965.htm
89. Novartis. “Afinitor (Everoliums) Tablets.” http://www.afinitor.com/everolimus-1.jsp?usertrack.filter_ applied=true&NovaId=2935377031735435211
90. American Cancer Society. “Breast Cancer Facts and Figures 2015-2016.” http://www.cancer.org/acs/groups/content/@research/ documents/document/acspc-046381.pdf
91. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf
92. Honey, K. “Ongoing Progress Against Cancer: New Breast Cancer Therapeutic Approved.” Cancer Research Catalyst. February 10, 2015. http://blog.aacr.org/fda-approval-palbociclib/
93. U.S. Food and Drug Administration. “Palbociclib (IBRANCE Capsules).” February 19, 2016. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm487080.htm
94. Broderick, J. “Palbociclib Combo Approved by FDA for Pretreated HR+/HER2-Negative Breast Cancer.” Target Oncology. February 22, 2016. http://www.targetedonc.com/news/palbociclib-combo-approved-fda-pretreated-hr-her2-negative-breast-cancer
95. American Society of Clinical Oncology. “Neratinib Extends Invasive DFS in HER2-Positive Early-Stage Breast Cancer.” May 31, 2015. http://am.asco.org/neratinib-extends-invasive-dfs-her2-positive-early-stage-breast-cancer
96. American Cancer Society. “Breast Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf 97. Roche. “Investor Update - Roche presents early data on investigational cancer immunotherapy atezolizumab in combination with nab-
paclitaxel chemotherapy in patients with specific type of advanced breast cancer.” December 11, 2015. http://www.roche.com/investors/ updates/inv-update-2015-12-11.htm
98. National Cancer Institute. “Immunotherapy: Using the Immune System to Treat Cancer.” http://www.cancer.gov/research/areas/ treatment/immunotherapy-using-immune-system
99. Broderick, J. “Pembrolizumab Continues to Show Promise in Breast Cancer.” Oncology Live. December 12, 2015. http://www.onclive. com/conference-coverage/sabcs-2015/pembrolizumab-continues-to-show-promise-in-breast-cancer
100. Helwick, C. “SABCS 2014: Pembrolizumab Holds Promise in Breast Cancer, Early Studies Suggest.” ASCO Post. December 10, 2014. http://www.ascopost.com/News/20659
101. American Cancer Society. “Cancer Vaccines.” http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/ immunotherapy/immunotherapy-cancer-vaccines
102. Venkataswarup, T, et al. “Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer.” Clinical Cancer Therapy. December 1, 2014. http://clincancerres.aacrjournals.org/content/20/23/5964.full. pdf+html
103. American Cancer Society. “Types of targeted therapies used to treat cancer.” http://www.cancer.org/treatment/ treatmentsandsideeffects/treatmenttypes/targetedtherapy/targeted-therapy-types
104. U.S. Food and Drug Administration. “FDA approves Lynparza to treat advanced ovarian cancer.” December 19, 2014. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm
105. Adis R&D Insight Database. Accessed May 2016.
106. National Cancer Institute. “HPV and Cancer.” http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-fact-sheet 107. American Cancer Society. “Cervical Cancer.” http://www.cancer.org/acs/groups/cid/documents/webcontent/003094-pdf.pdf
108. American Cancer Society. “What are the key statistics about cervical cancer?” http://www.cancer.org/cancer/cervicalcancer/ detailedguide/cervical-cancer-key-statistics
109. American Cancer Society. “What are the key statistics about cervical cancer?” http://www.cancer.org/cancer/cervicalcancer/ detailedguide/cervical-cancer-key-statistics
110. Centers for Disease Control and Prevention. “HPV Vaccination Information for Young Women.” http://www.cdc.gov/std/hpv/STDFact- HPV-vaccine-young-women.htm
111. National Cancer Institute. “Preventing Cervical Cancer: The Development of HPV Vaccines.” http://www.cancer.gov/research/progress/ discovery/hpv-vaccines
112. National Institutes of Health. “Cervical Cancer.” https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76
113. Centers for Disease Control and Prevention. “Morbidity and Mortality Weekly Report (MMWR): CDC Grand Rounds: Reducing the Burden of HPV-Associated Cancer and Disease.” January 31, 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6304a1.htm 114. National Institutes of Health. “Cervical Cancer.” https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76
115. National Institutes of Health. “Cervical Cancer.” https://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76
116. National Cancer Institute. “Preventing Cervical Cancer: The Development of HPV Vaccines.” http://www.cancer.gov/research/progress/ discovery/hpv-vaccines
117. National Cancer Institute. “Preventing Cervical Cancer: The Development of HPV Vaccines.” http://www.cancer.gov/research/progress/ discovery/hpv-vaccines
118. U.S. Food and Drug Administration. “FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus Rapid Approval Marks Major Advancement in Public Health.” June 8, 2006. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108666.htm
119. Markowitz, L, et al. “Prevalence of HPV After Introduction of the Vaccination Program in the United States.” Pediatrics. March 2016. http://pediatrics.aappublications.org/content/early/2016/02/19/peds.2015-1968.
120. U.S. Food and Drug Administration. “CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant].” Accessed April 2016. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
121. Centers for Disease Control and Prevention. “Morbidity and Mortality Weekly Report (MMWR): CDC Grand Rounds: Reducing the Burden of HPV-Associated Cancer and Disease.” January 31, 2014. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6304a1.htm 122. American Cancer Society. “FDA Approves Gardasil 9 HPV Vaccine.” January 8, 2015. http://www.cancer.org/cancer/news/news/fda-
approves-gardasil-9-hpv-vaccine
123. U.S. Food and Drug Administration. “Patient Information about GARDASIL 9.” Accessed April 2016. http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426460.pdf
124. American Cancer Society. “FDA Approves GARDASIL®9HPV Vaccine.” January 8, 2015. http://www.cancer.org/cancer/news/news/fda- approves-gardasil-9-hpv-vaccine
125. Merck. “FDA Approves Merck’s HPV Vaccine, GARDASIL®9, to Prevent Cancers and Other Diseases Caused by Nine HPV types – Including Types that Cause About 90% of Cervical Cancer Cases.” December 11, 2014. http://www.mercknewsroom.com/news- release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-gardasil9-prevent-cancers-an.
126. Centers for Disease Control and Prevention. “HPV Vaccines: Vaccinating Your Preteen or Teen.” http://www.cdc.gov/hpv/parents/ vaccine.html
127. Centers for Disease Control and Prevention. “HPV Vaccination Information for Young Women.” http://www.cdc.gov/std/hpv/STDFact- HPV-vaccine-young-women.htm
128. Centers for Disease Control and Prevention. “Morbidity and Mortality Weekly Report (MMWR): Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices.” March 27, 2015. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm
129. Hoffman, J. “HPV Sharply Reduced in Teenage Girls Following Vaccine, Study Says.” The New York Times. February 22, 2016. http:// www.nytimes.com/2016/02/22/health/vaccine-has-sharply-reduced-hpv-in-teenage-girls-study-says.html?_r=0
130. Markowitz, L, et al. “Prevalence of HPV After Introduction of the Vaccination Program in the United States.” Pediatrics. March 2016. http://pediatrics.aappublications.org/content/early/2016/02/19/peds.2015-1968.
131. Markowitz, L, et al. “Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010.” The Journal of Infectious Diseases. June 19, 2013. http://jid.oxfordjournals.org/content/early/2013/06/18/infdis.jit192.full